Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER

(PFE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Over the last seven days, analysts have been revising upwards their EPS estimates for the company.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • Based on current prices, the company has particularly high valuation levels.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The technical configuration over the long term remains negative on the weekly chart below the resistance level at 40.01 USD
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
PFIZER-16.84%200 777
JOHNSON & JOHNSON0.01%346 602
ROCHE HOLDING AG18.02%248 022
MERCK AND COMPANY10.38%215 942
NOVARTIS14.95%199 287
NOVO NORDISK AS17.25%121 422
AMGEN3.15%120 420
ASTRAZENECA17.76%115 078
SANOFI8.45%113 522
ABBVIE-20.13%108 861
GLAXOSMITHKLINE12.33%105 134
ELI LILLY AND COMPANY-6.36%99 196
BRISTOL-MYERS SQUIBB COMPAN..-0.71%84 422
CELGENE CORPORATION56.92%71 278
BAYER AG7.69%67 206
ALLERGAN PLC26.51%55 467
More Results
Financials (USD)
Sales 2019 51 498 M
EBIT 2019 18 946 M
Net income 2019 12 980 M
Debt 2019 32 534 M
Yield 2019 3,95%
P/E ratio 2019 15,9x
P/E ratio 2020 16,0x
EV / Sales2019 4,53x
EV / Sales2020 4,87x
Capitalization 201 B
Upcoming event on PFIZER
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes